Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

Clinuvel Pharmaceuticals Limited (ASX:CUV) is pleased to announce that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval, with immediate effect, to commence Phase III clinical trials of Clinuvel’s photo-protective drug, CUV1647, in Polymorphous Light Eruption (PLE). PLE (or PMLE) is a condition also known as moderate to severe sun-poisoning in patients following exposure to UV-radiation. The disease is characterised by a severe skin rash marked by red blisters, vesicles and patches presented on areas of sun exposed skin. The reported incidence of PLE varies between 10-20%. The current therapy available to patients essentially consists of sun…
Monday, 22 January 2007 11:00

Appendix 3B

Appendix 3B
Tuesday, 13 April 2010 06:15

2010 Press Coverage

Written by
{modulepos content2} To receive regular updates, including all of Clinuvel's announcements, you can subscribe to our email database here. DateTitleLink 09/11/2010 Clinuvel taking right approach: FDA Link 31/08/2010 Clinuvel adds to family Link 27/08/2010 Clinuvel seeks thriller repigmentation Link 21/07/2010 Clinuvel - Most interesting logos in Biopharma Link 17/07/2010 SurModics drug delivery tech has day in the sun with Clinuvel Link 16/07/2010 SurModics signs license agreement for UV treatment technology Link 13/07/2010 New drug may bring sufferers light relief Link 13/07/2010 Clinuvel Drug Offers Relief for Rare Light Sensitivity Malady, Study Shows Link 09/07/2010 Clinuvel signs first manufacturing deal for Scenesse…
Page 54 of 54

Quick Links